A downward trend of the ratio of influenza RNA copy number to infectious viral titer in hospitalized influenza a-infected patients

Open Forum Infectious Diseases

Volumn 2, Issue 4, 2015, Pages

  Van Wesenbeeck, Liesbeth ^a   D'Haese, David ^a   Tolboom, Jeroen ^b   Meeuws, Hanne ^a   Dwyer, Dominic E ^c   Holmes, Mark ^d   Ison, Michael G ^e   Katz, Kevin ^f   McGeer, Allison ^f   Sadoff, Jerald ^b   Weverling, Gerrit Jan ^b   Stuyver, Lieven ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b Janssen Infectious Diseases and Vaccines   (Netherlands)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ROYAL ADELAIDE HOSPITAL   (Australia)

^e NORTHWESTERN UNIVERSITY   (United States)

^f MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Infectious viral titer; Influenza A TCID50; Influenza A viral load; Influenza RNA copy number; Nasopharyngeal swabs

Indexed keywords

VIRUS RNA;

ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; GENE DOSAGE; HOSPITAL PATIENT; HUMAN; INFLUENZA A; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; THROAT CULTURE; VIRUS LOAD; VIRUS PARTICLE;

EID: 85014206228     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofv166     Document Type: Article

References (36)

1. Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1-24.
2. World Health Organization. Fact sheet seasonal influenza. Available at: http://www.who.int/mediacentre/factsheets/fs211/en/; 2014. Accessed 17 August 2015.
3. Hsu J, Santesso N, Mustafa R, et al. Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann Intern Med 2012; 156:512-24.
4. Louie JK, Yang S, Samuel MC, et al. Neuraminidase inhibitors for critically ill children with influenza. Pediatrics 2013; 132:e1539-45.
5. Muthuri SG, Myles PR, Venkatesan S, et al. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A (H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients. J Infect Dis 2013; 207:553-63.
6. Louie JK, Yang S, Acosta M, et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin Infect Dis 2012; 55:1198-204.
7. Yu H, Feng Z, Uyeki TM, et al. Risk factors for severe illness with 2009 pandemic influenza A (H1N1) virus infection in China. Clin Infect Dis 2011; 52:457-65.
8. Lee EH, Wu C, Lee EU, et al. Fatalities associated with the 2009 H1N1 influenza A virus in New York City. Clin Infect Dis 2010; 50:1498-504.
9. Lee N, Cockram CS, Chan PKS, et al. Antiviral treatment for patients hospitalized with severe influenza infection may affect clinical outcomes. Clin Infect Dis 2008; 46:1323-4.
10. Lee N, Choi KW, Chan PK, et al. Outcomes of adults hospitalized with severe influenza. Thorax 2010; 65:510-5.
11. McGeer A, Green KA, Plevneshi A, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007; 45:1568-75.
12. Siston AM, Rasmussen SA, Honein MA, et al. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA 2010; 303:1517-25.
13. Hurt AC. The epidemiology and spread of drug resistant human influenza viruses. Curr Opin Virol 2014; 8:22-9.
14. Hernandez JE, Adiga R, Armstrong R, et al. Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States. Clin Infect Dis 2011; 52:695-706.
15. Birnkrant D, Cox E. The emergency use authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med 2009; 361: 2204-7.
16. de Jong MD, Ison MG, Monto AS, et al. Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients. Clin Infect Dis 2014; 59:e172-85.
17. Ison MG, Fraiz J, Heller B, et al. Intravenous peramivir for treatment of influenza in hospitalized patients. Antivir Ther 2014; 19:349-61.
18. Whitley R, Laughlin A, Carson S, et al. Single dose peramivir for the treatment of acute seasonal influenza: integrated analysis of efficacy and safety from two placebo-controlled trials. Antivir Ther 2014; doi:10.3851/IMP2874.
19. Leang SK, Kwok S, Sullivan SG, et al. Peramivir and laninamivir susceptibility of circulating influenza A and B viruses. Influenza Other Respir Viruses 2014; 8:135-9.
20. Baek YH, Song MS, Lee EY, et al. Profiling and characterization of influenza virus n1 strains potentially resistant to multiple neuraminidase inhibitors. J Virol 2015; 89:287-99.
21. U.S. Department of Health and Human Services FDA, Center for Drug Evaluation and Research (CDER). Guidance for Industry. Influenza: Developing Drugs for Treatment and/or Prophylaxis, 2011. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegula toryInformation/Guidances/ucm091219.pdf. Accessed 17 August 2015.
22. Ison MG, de Jong MD, Gilligan KJ, et al. End points for testing influenza antiviral treatments for patients at high risk of severe and lifethreatening disease. J Infect Dis 2010; 201:1654-62.
23. Nauwelaers D, Vijgen L, Atkinson C, et al. Development of a real-time multiplex RSV detection assay for difficult respiratory samples, using ultrasone waves and MNAzyme technology. J Clin Virol 2009; 46:238-43.
24. Van Wesenbeeck L, Meeuws H, Van Immerseel A, et al. Comparison of the FilmArray RP, Verigene RV+, and Prodesse ProFLU+/FAST+ multiplex platforms for detection of influenza viruses in clinical samples from the 2011-2012 influenza season in Belgium. J Clin Microbiol 2013; 51:2977-85.
25. World Health Organization. CDC Protocol of Real-Time RT-PCR for Swine Influenza A(H1N1), 2009. Available at: http://www.who. int/csr/resources/publications/swineflu/CDCrealtimeRTPCRprotocol_20090428.pdf. Accessed 17 August 2015.
26. Van Wesenbeeck L, Meeuws H, D'haese D, et al. Sampling variability between two mid-turbinate swabs of the same patient has implications for influenza viral load monitoring. Virol J 2014; 11:233.
27. Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am J Epidemiol 1938; 27:493-7.
28. Thiebaut R, Jacqmin-Gadda H. Mixed models for longitudinal left-censored repeated measures. Comput Methods Programs Biomed 2004; 74:255-60.
29. Lyles RH, Williams JK, Chuachoowong R. Correlating two viral load assays with known detection limits. Biometrics 2001; 57:1238-44.
30. Meschi S, Selleri M, Lalle E, et al. Duration of viral shedding in hospitalized patients infected with pandemic H1N1. BMC Infect Dis 2011; 11:140.
31. Leekha S, Zitterkopf NL, Espy MJ, et al. Duration of influenza A virus shedding in hospitalized patients and implications for infection control. Infect Control Hosp Epidemiol 2007; 28:1071-6.
32. Lu PX, Deng YY, Yang GL, et al. Relationship between respiratory viral load and lung lesion severity: a study in 24 cases of pandemic H1N1 2009 influenza A pneumonia. J Thorac Dis 2012; 4:377-83.
33. Giannella M, Alonso M, Garcia de Viedma D, et al. Prolonged viral shedding in pandemic influenza A(H1N1): clinical significance and viral load analysis in hospitalized patients. Clin Microbiol Infect 2011; 17:1160-5.
34. Fraaij P, Schutten M, Javouhey E, et al. Viral shedding and susceptibility to oseltamivir in hospitalized immunocompromized patients with influenza in the Influenza Resistance Information Study (IRIS). Antivir Ther 2015; doi:10.3851/IMP2957.
35. Stephan C, Hill A, SawyerW, et al. Impact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials*. HIV Med 2013; 14:284-92.
36. Perry CM. Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C. Drugs 2012; 72:619-41.